![]() Pfizer announced that it is introducing three new biosimilars, ZIRABEV™ (bevacizumab-bvzr), RUXIENCE™ (rituximab-pvvr) and TRAZIMERA™ (trastuzumab-qyyp) in the United States (U.S.). Pfizer will become the first company to bring three oncology monoclonal antibody (mAb) biosimilar treatments to the U.S. PFIZER BRINGS THREE NEW BIOSIMILARS TO U.S. An additional 50 boxes have been provided to the Chinese Center for Disease Control and Prevention for laboratory-based investigations (drug-screening for antiviral properties against 2019-nCoV). (JNJ) has also donated 300 boxes of HIV med Prezcobix (darunavir/cobicistat) to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University for use in research to support efforts in finding a solution against 2019-nCoV. The vaccine program will leverage Janssen's AdVac® and PER.C6® technologies 29, 2020 9:11 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. J&J enters coronavirus fray with planned vaccine Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat #ICD 10 CODE FOR DM1 WITH HYPOGLYCEMIA TRIAL#WATERTOWN, Mass.-(BUSINESS WIRE)- FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the achievement of clinical development milestones for two of its exclusively-licensed, clinical-stage products to Boehringer Ingelheim (BI) and Bristol-Myers Squibb Company (BMS) (NYSE:BMY).īI initiated a Phase 1 clinical trial for BI 1701963, a SOS1:KRAS inhibitor 31, 2020 /PRNewswire/ - AbbVie ( ABBV)įORMA Reports Achievement of Early-stage Clinical Development Milestones for Assets Licensed Exclusively to Boehringer Ingelheim and Bristol-Myers Squibbīoehringer Ingelheim initiates Phase 1 clinical trial for SOS1:KRAS inhibitor BI 1701963, a FORMA-discovered, BI-licensed protein-protein interaction program for patients with advanced, KRAS-mutated solid tumorsīristol-Myers Squibb ( BMY) initiates Phase 1B clinical trial in patients with advanced or unresectable solid tumors for FORMA-discovered, Celgene-licensed pan BET inhibitor CC-95775 #ICD 10 CODE FOR DM1 WITH HYPOGLYCEMIA PLUS#Represents third positive CHMP opinion for VENCLYXTO further supports the growing utility of the therapy across multiple lines of CLL - Positive opinion based on data from Phase 3 CLL14 trial, which showed that patients who completed one year of treatment with VENCLYXTO plus obinutuzumab had prolonged progression-free survival and higher rates of minimal residual disease negativity compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |